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Abstract
Background: Farber Disease is an autosomal-recessively inherited, lysosomal storage disorder caused by
acid ceramidase deficiency and associated with distinct clinical phenotypes. Children with significant
neurological involvement usually die early in infancy, whereas patients without or only mild neurological
findings suffer from progressive joint deformation and contractures, subcutaneous nodules, inflammatory,
periarticular granulomas, a hoarse voice and finally respiratory insufficiency caused by granuloma
formation in the respiratory tract and interstitial pneumonitis leading to death in the third or fourth decade
of live. As the inflammatory component of this disorder is caused by some kind of leukocyte dysregulation,
allogeneic hematopoietic stem cell transplantation can restore a healthy immune system and thus may
provide a curative option in Farber Disease patients without neurological involvement. Previous stem cell
transplantations in two children with severe neurological involvement had resulted in a disappointing
outcome, as both patients died of progressive deterioration of their neurological status. As a consequence,
stem cell transplantation does not appear to be able to abolish or even reduce the neurotoxic effects of
the abundant ceramide storage in the brain.
Methods: After myeloablative, busulfan-based preparative regimens, four Farber Disease patients without
neurological involvement received an allogeneic hematopoietic stem cell transplantation from related and
unrelated donors. Stem cell source was BM in three patients and PBSC in one patient; GvHD-prophylaxis
consisted of CsA and short course MTX.
Results and discussion: In all patients, HSCT resulted in almost complete resolution of granulomas and
joint contractures, considerable improvement of mobility and joint motility without relevant therapy-
related morbidities. All patients are alive and well at this point with stabile donor cell chimerism and
without evidence of chronic GvHD or other late sequelae of stem cell transplantation.
Conclusion: Allogeneic hematopoietic stem cell transplantation provides a promising approach for
Farber Disease patients without neurological involvement.
Published: 29 June 2007
Pediatric Rheumatology 2007, 5:15 doi:10.1186/1546-0096-5-15
Received: 19 February 2007
Accepted: 29 June 2007
This article is available from: http://www.ped-rheum.com/content/5/1/15
© 2007 Ehlert et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 7
(page number not for citation purposes)
Pediatric Rheumatology 2007, 5:15 http://www.ped-rheum.com/content/5/1/15Part I: Clinical presentation of Farber Disease
Background: First description of Farber Disease
Ceramidase deficiency (Farber lipogranulomatosis or Far-
ber Disease), first described as an inborn storage disease
by Farber and coworkers [1,2], leads to tissue accumula-
tion of ceramide due to deficient activity of lysosomal
ceramidase.
The clinical presentation of Farber Disease (FD) is charac-
terized by the appearance of subcutaneous skin nodules,
ordinarily near the joints, most often interphalangeal,
wrist, elbow and ankle joints, or over points of mechani-
cal pressure. These manifestations are very painful and
lead to progressive joint stiffness, limitation of motion by
contractures and finally to immobilization and deforma-
tion of joints. Also, a characteristic sign of FD is the devel-
opment of a progressive hoarseness due to laryngeal
involvement [4].
Beside these major manifestations seven phenotypes have
been described which differ in severity and additional
organ involvement, like the lungs, nervous system, heart
and lymph nodes [4]. Dependent on residual lysosomal
ceramidase turnover, patients have a variable degree of
central nervous system disease, leading to progressive
neurologic deterioration. In most cases the neuronal dys-
function rather than the general physical dystrophy seems
to limit the duration of FD [3]. As well, patients with FD
may die due to pulmonary disease with interstitial pneu-
monia.
First symptoms usually appear between the newborn
period and the first birthday. Milder forms of type 3 were
described with onset at 20 months of age. Clinical mani-
festation in type 5 of FD, dominated by neurologic deteri-
oration, begins at 1 to 2 1/2 years of life. Patients mainly
die within the first years of life, but prolonged courses in
patients without severe CNS disease may also be observed
[5].
Phenotypes of Farber Disease
Type 1 is the classic form of the disease with early subcu-
taneous nodules, joint involvement and hoarseness in all
cases. Progressive neurologic involvement and lung dis-
ease are reported in many cases [4].
In contrast, type 2 and 3 patients show only slight or no
symptoms of central nervous system disease. However,
they still have a severe disease as a result of granuloma-
tous inflammation leading to subcutaneous nodules,
joint pain and contractures, hoarseness, failure to thrive
and respiratory involvement [4].
Patients with type 4 FD present with severe neurologic
deterioration and large hepatosplenomegaly already in
the neonatal period. Histopathology shows massive gran-
ulomatous infiltrations by accumulating macrophages in
liver, spleen, lymphoid tissue, thymus and lungs [6].
The major clinical presentation in type 5 patients is a pro-
gressive CNS dysfunction, beginning at 1 to 2 1/2 years of
life and manifestating in tetraplegia, loss of speech, myo-
clonia, seizures and mental retardation [7].
Type 6 is a combination of type 1 FD and Sandhoff disease
[8], another lysosomal storage disorder caused by hex-
osaminidase A and B enzyme defects. Both acid cerami-
dase and hexosaminidase A and B are involved in the
catabolism of glycosphingolipids.
One patient is classified as type 7, showing a combined
deficiency of glucocerebrosidase, galactocerebrosidase
and ceramidase due to a mutation of prosaposin, the pre-
cursor protein for two sphingolipid activator proteins [9].
Diagnosis of Farber Disease
In typical cases of type 1 FD the clinical triad of subcuta-
neous nodules, joint and laryngeal involvement verifies
the disease. When typical features are missing, diagnosis is
confirmed by determination of acid ceramidase activity,
which is less than 6 percent of control values, measured in
cultured skin fibroblasts, white blood cells or amniocytes
[4]. Another diagnostic approach is the demonstration of
typical histopathologic features on biopsy, showing gran-
ulomas with macrophages containing lipid cytoplasmic
inclusions in subcutaneous nodules or other tissues [2].
Determination of ceramide accumulation in tissues by
chromatography or mass spectrometry is also an estab-
lished diagnostic test for FD [4].
Part II: Etiology and pathogenesis of Farber 
Disease
The curative effect of HSCT on the inflammatory symp-
toms in FD indicates that the granulomatous inflamma-
tion in these patients is not a consequence of mere
ceramide storage but reflects a dysregulation of leukocyte
functions, probably due to the intracellular role of cera-
mide in intracellular signal transduction [16]. However,
the sequence of molecular mechanisms leading from a
defect in ceramide metabolism to chronic granulomatous
inflammation still needs elucidation. Alterations of recep-
tor-mediated apoptosis by ceramide accumulation in
inflammatory cells may be one of the mechanisms under-
lying abnormal granuloma formation.
Recent evidence suggests that the sphingolipid ceramide
plays an important role as a second messenger in a
number of signal transduction pathways. Many cellular
responses to extracellular stimuli have been linked to the
intracellular generation of ceramide, especially the induc-Page 2 of 7
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agents. Ceramide has been proposed to mediate apopto-
sis, because many pro-apoptotic stimuli induce the pro-
duction of ceramide and treatment with exogenously
added ceramides can induce apoptotic cell death [14].
In a previous study we have shown that cells obtained
from a FD patient showed remarkable changes in their
sensitivity to different apoptotic stimuli [15]. When
treated with staurosporine, chemotherapeutic drugs or
ionizing radiation, FD cells underwent apoptosis and acti-
vated caspases comparable to control cells. However, due
to the lack of ceramidase, cell-permeable ceramides had a
stronger pro-apoptotic activity in Farber cells than in con-
trols. Interestingly, we consistently observed an acceler-
ated rate of lymphocyte death in FD upon activation of
the death receptor molecule fas (CD95). These data sug-
gest that ceramide does not play an essential role as a gen-
eral trigger or second messenger in all kinds of apoptosis,
but may rather act as a specific amplifier of receptor-
induced cell death [15]. There is growing evidence that
generation of ceramide increases membrane fluidity and
raft formation in the plasma membrane, thereby facilitat-
ing receptor mediated signalling. Indeed, recent studies
showed that ceramide may be critically involved in cap
formation, clustering, and activation of the CD95 receptor
[12,13].
As a major symptom FD patients exhibit chronic destruc-
tive joint inflammation resembling rheumatoid arthritis.
Indeed, increased CD95 receptor/ligand interaction has
been implicated in the pathogenesis of inflammatory
arthritis [10,11]. It may therefore be speculated that
increased CD95 signalling mediated by elevated ceramide
levels is involved in the inflammatory arthritis of FD.
Part III: Therapeutic approaches to Farber 
disease patients without CNS involvement
Introduction
For some decades now, allogeneic hematopoeitic stem
cell transplantation has proven to provide a potential, cur-
ative approach to malignant [17] and non-malignant dis-
eases. Additionally, it has also shown efficacy in some
inherited disorders, predominantly primary immunodefi-
ciencies and lysosomal storage disorders [19,24]. Symp-
toms of disease in these metabolic disorders are usually
caused by the lack of enzyme activity. The transplantation
of hematopoetic stem cells from a healthy donor can be a
source of a sufficient amount of enzyme and thus abolish
or at least decrease or stabilize symptoms of disease in
some patients [18,20-22].
The etiology of Farber disease is the lack of acid cerami-
dase, and subsequently there is an increased storage of
ceramide in several organs and tissues [4]. However, as
already illuminated in the previous two chapters of this
article, the main symptoms of disease in these patients, at
least in those without involvement of the central nervous
system, are caused by some kind of leukocyte dysregula-
tion [15]. The dysfunction of the immune system results
in the inflammatory component of the disorder with
painful swelling of several joints, granuloma formation,
contractures and inflammatory airway involvement. Cur-
rent management for these patients has therefore focused
on pain therapy, physcial therapy, surgical correction of
severe contractures and anti-inflammatory medication.
The affected patients usually die in the second decade of
their lives as a consequence of granuloma formation in
the respiratory tract and their immobility with recurrent
episodes of pneumonia and resulting respiratory insuffi-
ciency [4].
Previous reports on allogeneic HSCT in Farber disease 
patients
The first reports on hematopoietic stem cell transplantion
in two Farber disease patients were published in 1989 and
2000 by Souillet and Yeager [25,26]. However, both chil-
dren had a subtype of Farber disease with involvement of
the central nervous system and died because of a deterio-
ration of their neurological status. So, as is also the case in
other lysosomal storage disorders with severe CNS disease
[23], hematopoietic stem cell transplantation does not
seem to provide a benefit for these children, as it is not
able to abolish or even reduce the neurotoxic effects of
excessive ceramide accumulation in the brain. However,
as HSCT can provide a healthy immune system and thus
correct the abnormal inflammatory response and symp-
toms of disease, there could be an option for hematopoi-
etic stem cell transplantation in those children with a
predominance of the inflammatory component of the dis-
order. Additionally, resolution of granulomas after
hematopoietic stem cell transplantation could also be
demonstrated in children with central nervous system
involvement [25,26].
Present experience of allogeneic HSCT in Farber disease 
patients without CNS involvement
Starting in 2001, three patients in Muenster [27] and one
patient in Hamburg have been transplanted so far. Diag-
nosis was confirmed by measurement of the activity of
acid ceramidase in fibroblast cultures (patients #1, #2 and
#3 in Toulouse, France, and patient #4 in Baltimore,
USA). All patiens had the typical findings of Farber disease
with granuloma formation, a hoarse voice, painful swell-
ing of their joints with partially severe contractures and
restriction of mobility. Table 1 shows the transplant
related data of these patients.
The preparative regimen, consisting of intravenous
(patients #1 to #3) or oral busulfan (patient #4) andPage 3 of 7
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renal, skin or lung toxicities were observed. In patients #1,
#3 and #4 bone marrow was the stem cell source, in
patient #2 peripheral blood stem cells were used; no in-
vitro-T cell depletion was performed. GvHD prophylaxis
consisted of ciclosporine and short course methotrexate.
Engraftment was noted between days +12 and +18.
Patients #1, #2 and #3 developed mild acute GvHD, but
no evidence of chronic GvHD so far. Therapy for acute
GvHD consisted of steroids in all affected patients, and in
patient #3, of additional tacrolimus instead of
ciclosporine, as she experienced ciclosporine-induced-
neurotoxicity. Transplant related morbidity in our
patients was moderate. CMV-reactivation and -colitis in
patients #2 and #3, respectively, was controlled by intra-
venous ganciclovir. For treatment of Clostridium difficile
enteritis and Staphylococci bacteremia, patient #1 was
given oral vancomycin and iv teicoplanin. On routine
ophthalmological examination on day +100, patient #1
was diagnosed with papillary edema, most probably due
to elevated intracranial pressure as a consequence of med-
ication with ciclosporine; she was switched to tacrolimus,
although she did not suffer from clinical neurotoxicity. In
contrast, clinical signs of neurotoxicity by ciclosporine
were observed in patient #3; she presented with a general-
ized seizure, stroke-like symptoms and the characteristic
findings in MR imaging studies. Both patients #1 and #3
were switched from ciclosporine to tacrolimus without
further difficulties. Hemiparesis in patient #3 gradually
resolved within a few months.
In contrast to the natural course of disease in Farber
patients, which is characterized by progressive joint defor-
mation, immobility, pain and finally restriction to wheel-
chairs, all of the transplanted patients demonstrated a
gradual improvement in mobility, reduced number of
joints with restricted motion, less pain and significant
gain of function. Prior to her transplant, patient #1 was
almost wheel-chair bound and could hardly walk, as she
suffered from severe contractures in numerous joints. Fig-
ures 1 to 3 clearly illustrate the substantial benefit of
HSCT in this patient, as shown with the pre- and post-
transplant status of her hands.
Patient #4 was a young woman at the time of her trans-
plant, having a milder course of disease compared to the
other patients, which might reflect a different subtype on
a molecular basis. The reason for HSCT was the need of
numerous surgical procedures in her legs to improve
mobility. Currently, all patients are seen at least twice
yearly by the outpatient BMT unit; additionally, all chil-
dren are evaluated by pediatric rheumatology once yearly.
Inflammatory markers (ESR, leukocyte count, CRP) are
checked regularly, however, no data is available with
regard to specific granulocyte activation markers. Table 2
summarizes the findings in the post-transplant course of
our patients.
Summary
It is clearly evident that the present experience with
hematopoietic stem cell transplantation in Farber Disease
is still limited. HSCT may not be appropriate for patients
with CNS involvement as ceramide neurotoxicity may not
be reversible by stem cell transplantation. After a myelo-
ablative, busulfan-based preparative regimen, a rapid
engraftment was demonstrated with only moderate acute
GvHD, no signs of chronic GvHD and low therapy-related
morbidity. Donor cell chimerism is between 90 and 100%
which seems to be sufficient for important reduction of
disease-specific symptoms as all transplanted patients had
a considerable improvement in joint mobility and a
decreasing number of granulomas.
In conclusion, despite the preliminary nature of the data
on hematopoietic stem cell transplantation in Farber Dis-
ease without central nervous system involvement, we
Table 1: Transplant-related data of patients
Parameter Patients
Patient number and gender #1, female #2, male #3, female #4, female
Patient origin Muenster Muenster Muenster Hamburg
Age at SCT 3 years 3 years 2 years 21 years
Preparative regimen Bu/Cy Bu/Cy/ATG Bu/Cy Bu/Cy/ATG
Stem cell source and dose (no T-cell 
depletion)
BM (MRD), 11.3 × 106 CD34 PBSC (MUD), 25 × 106 CD34 BM (MRD), 5.6 × 106 CD34 BM (MRD), 4.2 × 106 CD34
GvHD prophylaxis CsA, MTX CsA, MTX CsA, MTX CsA, MTX
Neutrophil engraftment day +14 day +12 day +18 day +14
Acute/chronic GvHD grade II of gut/none grade I of gut/none grade II of skin/none none
Therapy of acute/chronic GvHD steroids/none steroids/none steroids + tacrolimus/none none
Infections Clostridium difficile enteritis, 
bacteremia with Staphylococci
CMV reactivation CMV colitis none
Toxicities CsA-neurotoxicity None CsA-neurotoxicity suspected VOD
Current donor cell chimerism 91% 95% 90% 99%Page 4 of 7
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CD cluster of differentiation
CMV cytomegalovirus
CNS central nervous system
CRP C reactive protein
CsA ciclosporin A
CY cyclophosphamide




HSCT hematopoietic stem cell transplantation
Pre-transplant status of patient #1, right hand (palmar view), with identical findings as described in Figure 1Figu e 2
Pre-transplant status of patient #1, right hand (palmar view), 
with identical findings as described in Figure 1.
Table 2: Post-transplant follow-up of patients
Parameter Patients
Patient number and 
gender
#1, female #2, male #3, female #4, female
Patient origin Muenster Muenster Muenster Hamburg
Time point of follow-
up
prior to SCT day +450 prior to SCT day +200 prior to SCT day +270 prior to SCT day +958
ESR (mm, first hour, 
Westergren)
38 9 53 12 25 13 no data available
Time point of follow-
up
prior to SCT day +1800 prior to SCT day +1560 prior to SCT day +990 prior to SCT day +958
Number of nodules 58 0 39 0 18 0 pre Tx-nodules mainly dissolved, no new nodules
Number of joints with 
restricted mobility
26 0 24 0 10 0 almost all joints affected, however considerable 
improvement after HSCT
Legend: The clinical evaluation of patients has been followed more closely, so laboratory data (i.e. ESR) are not available at each time-point of 
follow-up.
Pre-transplant status of patient #1, right hand (thumb), with inflammatory nodulesFigu e 1
Pre-transplant status of patient #1, right hand (thumb), with 
inflammatory nodules.Page 5 of 7
(page number not for citation purposes)
Pediatric Rheumatology 2007, 5:15 http://www.ped-rheum.com/content/5/1/15IV intravenous
MR magnetic resonance
MRD matched related donor
MTX methotrexate
MUD matched unrelated donor
PBSC peripheral blood stem cells




The author(s) declare that they have no competing inter-
ests.
Authors' contributions
The concept of allogeneic stem cell transplantation in
these children was developed by Josef Vormoor and
Johannes Roth. Michael Frosch describes the clinical phe-
notypes of FD, Johannes Roth has written the part on eti-
ology and pathogenesis, Karoline Ehlert part III on recent
experiences with stem cell transplantation. Natalja Fehse
and Axel Zander have reported the outcome of their
patient transplanted in Hamburg. All authors have read
and approved the final manuscript.
Informed consent
Written informed consent for the publication of the pho-
tographs has been obtained by the patients respectively
their parents.
References
1. Farber S: A lipid metabolic disorder: disseminated lipogranu-
lomatosis: a syndrome with similarity to, and important dif-
ference from, Niemann-Pick and Hand-Schüller-Christian
disease.  American Journal of Diseases in Childhood 1952,
84(4):499-500.
2. Farber S, Cohen J, Uzman LL: Lipogranulomatosis: a new lipo-
glycoprotein storage disease.  Journal of Mt Sinai Hospital N Y
1957, 24(6):816-837.
3. Levade T, Moser HW, Fensom AH, Harzer K, Moser AB, Salavayre R:
Neurodegenerative course in ceramidase deficiency (Farber
disease) correlates with the residual lysosomal ceramide
turnover in cultured living patient cells.  Journal of Neurological
Sciences 1995, 134(1-2):108-114.
4. Moser HW, Linke T, Fensom AH, Levade T, Sandhoff K: Acid
ceramidase deficiency: Farber lipogranulomatosis.  In The
Metabolic and Molecular Bases of Inherited Disease 8th edition. Edited
by: Scriver CR. New York: McGraw-Hill; 2001:3573-3585. 
5. Pavone L, Moser HW, Mollica F, Reitano C, Durand P: Farber's
lipogranulomatosis: Ceramidase deficiency and prolonged
survival in three relatives.  Johns Hopkins Medical Journal 1980,
147:193-196.
6. Antonarakis SE, Valle D, Moser HW, Kishimoto Y: Phenotypic var-
iability in siblings with Farber disease.  Journal of Pediatrics 1984,
104:406-409.
7. Eviatar L, Sklower SL, Wisniewski K, Feldman RS, Gochoco A: Far-
ber (lipogranulomatosis): An unusual presentation in a black
child.  Pediatric Neurology 1986, 2:371-374.
8. Fusch C, Huenges R, Moser HW, Sewell AC, Roggendorf W, Kuster-
man K, Harzer K: A case combined Farber's and Sandhoff's dis-
ease.  European Journal of Pediatrics 1989, 148:558-562.
9. Schnabel D, Schröder M, Furst W, Klein A, Hurwitz R, Zenk T,
Weber J, Harzer K, Paton BC, Poulos A, Suzuki K, Sandhoff K: Simul-
taneous deficiency of sphingolipid activator proteins 1 and 2
is caused by a mutation in the initiation codon of their com-
mon gene.  Journal of Biochemical Chemistry 1992, 267(5):3312-3315.
10. Hoang TR, Hammermuller A, Mix E, Kreutzer HJ, Goerlich R, Kohler
H, Nizze H, Thiesen HJ, Ibrahim SM: A proinflammatory role for
Fas in joints of mice with collagen-induced arthritis.  Arthritis
Research and Therapy 2004, 6(5):R404-414.
11. Ma Y, Liu H, Tu-Rapp H, Thiesen HJ, Ibrahim SM, Cole SM, Pope RM:
Fas ligation on macrophages enhances IL-1R1-Toll-like
receptor 4 signalling and promotes chronic inflammation.
Nature Immunology 2004, 5(4):380-387.
12. Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Koles-
nick R, Gulbins E: CD95 signalling via ceramide-rich mem-
brane rafts.  Journal of Biological Chemistry 2001,
276(23):20589-20596.
13. Cremesti A, Paris F, Grassme H, Holler N, Tschopp J, Fuks Z, Gulbins
E, Kolesnick R: Ceramide enables fas to cap and kill.  Journal of
Biological Chemistry 2001, 276(26):23954-23961.
14. Levade T, Jaffrezou JP: Signalling sphingomyelinases: which,
where, how and why?  Biochemical and Biophysical Acta 1999,
1438(1):1-17.
15. Burek C, Roth J, Koch HG, Harzer K, Los M, Schulze-Osthoff K: The
role of ceramide in receptor- and stress-induced apoptosis
studied in acidic ceramidase-deficient Farber disease cells.
Oncogene 2001, 20(45):6493-6502.
16. Mathias S, Pena LA, Kolesnick RN: Signal transduction of stress
via ceramide.  Biochemical Journal 1998, 335:465-480.
17. Sanders JE: Bone marrow transplantation for pediatric malig-
nancies.  Pediatric clinics of North America 1997, 44(4):1005-1020.
18. Vormoor J, Marquardt T: Hematopoietic cell transplantation in
inborn errors of metabolism.  Current opinion in organ transplanta-
tion 2004, 9:43-48.
19. Malatack JJ, Consolini DM, Bayever E: The status of hematopoi-
etic stem cell transplantation in lysosomal storage disease.
Pediatric Neurology 2003, 29(5):391-403.
18 months post-transplant status of patient #1 with complete resolution of inflammatory nodulesFigure 3
18 months post-transplant status of patient #1 with complete 
resolution of inflammatory nodules.Page 6 of 7
(page number not for citation purposes)
Pediatric Rheumatology 2007, 5:15 http://www.ped-rheum.com/content/5/1/15Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
20. Wilcox WR: Lysosomal storage disorders: The need for bet-
ter pediatric recognition and comprehensive care.  The Journal
of Pediatrics 2004, 144:S3-S14.
21. Schiffmann R, Brady RO: New prospects for the treatment of
lysosomal storage diseases.  Drugs 2002, 62(5):733-742.
22. Peters C, Steward CG: Hematopoietic cell transplantation for
inherited metabolic diseases: an overview of outcomes and
practice guidelines.  Bone marrow transplantation 2003, 31:229-239.
23. Baumann M, Korenke GC, Weddige-Diedrichs A, Wilichowski E,
Hunneman DH, Wilken B, Brockmann K, Klingebiel T, Niethammer
D, Kuehl J, Ebell W, Hanefeld F: Haematopoietic stem cell trans-
plantation in 12 patients with cerebral X-linked adrenoleu-
kodystrophy.  European Journal of Pediatrics 2003, 162:6-14.
24. Buckley RH: A historical review of bone marrow transplanta-
tion for immunodeficiencies.  Journal of allergy and clinical immunol-
ogy 2004, 113(4):793-800.
25. Souillet G, Guibaud P, Fensom AH, Maire I, Zabot MT: Outcome of
displacement bone marrow transplantation in Farber's dis-
ease: a report of a case.  In Correction of certain genetic diseases by
transplantation Edited by: Hobbs JR. London: COGENT;
1989:137-141. 
26. Yeager AM, Armfield-Uhas K, Coles CD, Davis PC, Krause WL,
Moser HW: Bone marrow transplantation for infantile ceram-
idase deficiency (Farber disease).  Bone marrow transplantation
2000, 26:357-363.
27. Vormoor J, Ehlert K, Groll AH, Koch HG, Frosch M, Roth J: Success-
ful hematopoietic stem cell transplantation in Farber dis-
ease.  The Journal of Pediatrics 2004, 144(1):132-134.Page 7 of 7
(page number not for citation purposes)
